FDA approves first buprenorphine implant for treatment of op
Aditya Bhatt
FDA approves first buprenorphine implant for treatment of opioid dependence
FDA approved the first buprenorphine implant (Probuphine) for the maintenance treatment of opioid dependence. As a part of complete treatment, Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine.

Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm. Probuphine should be inserted and removed surgically by health care provider who has completed the training and become certified through a restricted program called the Probuphine Risk Evaluation and Mitigation Strategy (REMS) program.

for more details

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm
A●●●●a B●●●t and 3 others like this
Like
Comment
Share